According to Iconovo, Japanese pharmaceutical company TOA Pharmaceuticals has placed a “significant” order for DPIs to be used in a feasibility study. Iconovo will produce two customized versions of the inhaler and will conduct the feasibility study with four different commercially available dry powder products to determine how those products perform in the Iconovo inhalers.
In December 2017, Iconovo and TOA signed a letter of intent for development of DPIs for the Japanese market. Iconovo CEO Orest Lastow notes that the order for the modified DPIs is the company’s first commercial deal in Japan.
Lastow said, “This is an important step forward in our cooperation with TOA Pharmaceuticals. Iconovo’s products are very well suited for many markets’ special requirements, and we are very pleased to be able to test and validate this. We expect this pilot study to help us achieve our goals and pave the way for several new projects in the coming years.”
“We are very happy to have a strong partner in the Japanese market,” he told OINPDnews.
Read the Iconovo press release.
